New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B / 대한소화기학회지
The Korean Journal of Gastroenterology
; : 144-149, 2011.
Article
em Ko
| WPRIM
| ID: wpr-151920
Biblioteca responsável:
WPRO
ABSTRACT
Over the past decade, advances in the antiviral therapy in patients with chronic hepatitis B have enabled the sustained suppression of hepatitis B viral replication and the prevention of progressive liver disease. Hepatitis B surface antigen (HBsAg) has been used to diagnose patients with hepatitis B virus infection. Recently, test for quantitative HBsAg titers are available and on-treatment HBsAg quantitations are used to predict treatment outcome. Serum HBV DNA levels have been shown to predict natural course of chronic hepatitis B infection. The HBV DNA levels have been reported to be positively correlated with the development of cirrhosis, hepatocellular carcinoma and related death. The baseline and on-treatment levels of HBV DNA are important factors for predicting treatment outcomes. In this article, we will discuss the role of HBV DNA and HBsAg quantitation during antiviral therapy.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Antivirais
/
Pirimidinonas
/
DNA Viral
/
Vírus da Hepatite B
/
Carcinoma Hepatocelular
/
Lamivudina
/
Hepatite B Crônica
/
Antígenos de Superfície da Hepatite B
/
Cirrose Hepática
/
Neoplasias Hepáticas
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
Ko
Revista:
The Korean Journal of Gastroenterology
Ano de publicação:
2011
Tipo de documento:
Article